Previsão

O preço-alvo médio dos analistas é € 21,66 (+74,54%). A mediana é € 20,80 (+67,61%).

Comprar	26
Manter	6
Vender	1

Notícias Ir para o feed de notícias

Ultragenyx stock plunges 45% after Phase‑3 trial failure for Apazunersen

The drug candidate Apazunersen (GTX‑102) failed in the approval‑relevant Phase‑3 Aspire trial for Angelman syndrome, missing both the primary and key secondary endpoints. The news triggered a premarket drop of about 45%. Analysts cut ratings and sharply reduced price targets (e.g., Evercore, Baird, JPMorgan, William Blair), since Apazunersen had been seen as a central pillar of Ultragenyx’s pipeline. The stock now faces a reassessment because an important growth driver is gone. » Mais em deraktionaer.de
Ultragenyx share falls 40% after failed phase‑3 study of apazunersen

Ultragenyx shares plunged more than 40% in after‑hours trading after the phase‑3 Aspire study of apazunersen in Angelman syndrome missed its primary and key secondary endpoints (cognitive Bayley‑4 raw score and MDRI). The safety profile matched phase‑1/2 results but showed no efficacy differences versus control. Ultragenyx will evaluate the apazunersen program and make a decision on its future, and will review business activities to define and implement significant cost reductions. » Mais em de.investing.com
Ultragenyx presents positive 96-week data on GSDIa gene therapy GENGLYCOS

In the phase 3 study of GENGLYCOS (DTX401), there was an average 61% reduction in daily cornstarch intake versus baseline after 96 weeks among treated and crossover participants. 67% of the original treatment group and 72% of the crossover group achieved at least a 50% reduction in cornstarch intake, and a proportion of patients were able to discontinue nighttime cornstarch entirely. GENGLYCOS received accelerated approval in the US for patients aged eight and older; continued approval depends on confirmatory studies. Common treatment-related adverse events included transient liver enzyme elevations, and several serious adverse events were reported during the efficacy analysis, including anaphylaxis and adrenal insufficiency. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Ultragenyx Pharmaceutical já distribuiu € 0,27 em dividendos. A última distribuição ocorreu em julho de 2022.

Dados financeiros da empresa

No último trimestre, Ultragenyx Pharmaceutical registou receitas de € 187,51 mi e um ganho líquido de -€ 80,61 mi

(EUR)	junho de 2026	YoY
Receitas	187,51 mi	32,74%
Ganho bruto	157,72 mi	29,55%
Ganho líquido	-80,61 mi	17,34%
EBITDA	-53,45 mi	31,03%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 1,22 bi
Número de ações	98,49 mi
Máximo/mínimo de 52 semanas	€ 34,57 - € 11,97
Dividendos	Não
Beta	0,32
PER (PE Ratio)	-2,45
PEG (PEG Ratio)	0,39
P/VC (PB Ratio)	-5,01
P/V (PS Ratio)	1,96

Perfil da empresa

Ultragenyx Pharmaceutical Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Identifizierung, den Erwerb, die Entwicklung und die Vermarktung neuartiger Produkte für die Behandlung seltener und extrem seltener genetischer Krankheiten in Nordamerika, Europa und international konzentriert. Zu den biologischen Produkten des Unternehmens gehören Crysvita (Burosumab), ein Antikörper gegen den Fibroblasten-Wachstumsfaktor 23 zur Behandlung der X-chromosomalen Hypophosphatämie und der tumorbedingten Osteomalazie; Mepsevii, eine Enzymersatztherapie zur Behandlung von Kindern und Erwachsenen mit Mukopolysaccharidose VII; Dojolvi zur Behandlung von Störungen der Oxidation langkettiger Fettsäuren; und Evkeeza (Evinacumab) zur Behandlung der homozygoten familiären Hypercholesterinämie. Zu den Produktkandidaten des Unternehmens gehören DTX401, ein Gentherapiekandidat mit dem Adeno-assoziierten Virus 8 (AAV8) zur Behandlung von Patienten mit der Glykogenspeicherkrankheit Typ Ia; DTX301, eine AAV8-Gentherapie zur Behandlung von Patienten mit Ornithintranscarbamylase; UX143, ein humaner monoklonaler Antikörper zur Behandlung der Osteogenesis imperfecta; GTX-102, ein Antisense-Oligonukleotid zur Behandlung des Angelman-Syndroms; UX701 zur Behandlung der Wilson-Krankheit; und UX053 zur Behandlung der Glykogenspeicherkrankheit Typ III. Ultragenyx Pharmaceutical Inc. hat Kooperations- und Lizenzvereinbarungen mit Kyowa Kirin Co, Ltd, der Saint Louis University, dem Baylor Research Institute, REGENXBIO Inc, Bayer Healthcare LLC, GeneTx, Mereo, der University of Pennsylvania, Arcturus Therapeutics Holdings Inc, Solid Biosciences Inc. und Daiichi Sankyo Co, Ltd. Ultragenyx Pharmaceutical Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Novato, Kalifornien.

Nome	Ultragenyx Pharmaceutical
CEO	Emil D. Kakkis
Sede	Novato, ca EUA
Site	ultragenyx.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	31/01/2014
Colaboradores	1.371